• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Syndax Pharmaceuticals, Inc.

News headline image
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
December 01, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 05, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
November 03, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
November 03, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
November 03, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Announces Participation in November Investor Conferences
October 30, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
October 27, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
October 24, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 03, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
September 19, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
September 05, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Announces Participation in September Investor Conferences
August 26, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 06, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update
August 04, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025
July 28, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 02, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
June 24, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
June 12, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
June 12, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 05, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Announces Participation in June Investor Conferences
May 29, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)
May 14, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
May 12, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Announces Participation in May Investor Conferences
May 08, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood
May 07, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update
May 05, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 02, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025
April 28, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
April 02, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
March 05, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap